View Cart  

FDA: Conduct Superiority Trials With PRO Endpoint for ABECB-COPD Drugs

Drugmakers should use superiority trials when developing antimicrobial drugs for the treatment of acute bacterial exacerbations of chronic bronchitis in patients with chronic obstructive pulmonary disease (ABECB-COPD), according to an updated FDA guidance.

To View This Article:


Subscribe To Clinical Trials Advisor

Buy This Article Now

Add this article to your cart for $25.00